AB SCIEX announce partnership programme to support biological research
AB SCIEX (Framingham, Massachusetts, USA) has announced the AB SCIEX Academic Partnership Programme to increase the number of scientists who benefit from the company?s assistance and resources for advancing research in proteomics, metabolomics and lipidomics.
AB SCIEX (Framingham, Massachusetts, USA) has announced the AB SCIEX Academic Partnership Programme to increase the number of scientists who benefit from the company’s assistance and resources for advancing research in proteomics, metabolomics and lipidomics. The company are linking with academic researchers to overcome the barriers put up by hard-to-obtain technologies that prevent advancements and breakthroughs in medicine and biology.
The programme hopes to simplify the grant-writing process for researchers and provide access to technical expertise and support in mass spectrometry and chromatography. The company will also provide sponsorships for promising research that shows exemplary use of LC–MS–MS.
One researcher who has benefitted from a collaborative relationship with AB SCIEX is Anne-Claude Gingras of the Samuel Lunenfeld Research Institute, Mount Sinai Hospital, Toronto, Canada. She commented, “I think that partnering with an industry leader such as AB SCIEX is invaluable for an academic researcher. Cooperation between academia and industry has been important in significant scientific advancements, and AB SCIEX has quite a bit of credibility from being part of some major breakthroughs.”
Ron Bonner, principal scientist, AB SCIEX, said, “We believe that the next great breakthroughs in biomedical research will come from network biology, so we are partnering with academic researchers around the world to help support their important research.”
For more information please visit ref="http://www.absciex.com">www.absciex.com
The Complexity of Oligonucleotide Separations
January 9th 2025Peter Pellegrinelli, Applications Specialist at Advanced Materials Technology (AMT) explains the complexity of oligonucleotide separations due to the unique chemical properties of these molecules. Issues such as varying length, sequence complexity, and hydrophilic-hydrophobic characteristics make efficient separations difficult. Separation scientists are addressing these challenges by modifying mobile phase compositions, using varying ion-pairing reagents, and exploring alternative separation modes like HILIC and ion-exchange chromatography. Due to these complexities, AMT has introduced the HALO® OLIGO column, which offers high-resolution, fast separations through its innovative Fused-Core® technology and high pH stability. Alongside explaining the new column, Peter looks to the future of these separations and what is next to come.
Metabolomics Analysis of Low Birth-Weight Infants Using UHPLC-MS/MS Following Lipid Emulsion
January 10th 2025A recent study aimed to directly compare the changes in serum metabolites among very low birth-rate (VLBW) infants following the administration of the soybean oil-based lipid emulsion and soybean oil, medium-chain triglycerides, olive oil, and fish oil (SMOF) lipid emulsion using untargeted metabolomics techniques.
Analyzing New Drug Modalities: An ISC 2024 Interview with Kelly Zhang
January 10th 2025At ISC 2024 in Liverpool, United Kingdom, LCGC International interviewed Kelly Zhang of Genentech about her work analyzing new drug modalities, such as mRNA, oligonucleotides, peptides, and cell and gene therapies.
